100
Participants
Start Date
October 15, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2027
Chidamide + Tislelizumab + chemotherapy (CapeOX )
Chidamide + Tislelizumab + chemotherapy (CapeOX regimen): 4 cycles of combination therapy (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; tislelizumab, 200mg/m2 iv.gtt; Day1,4,8,11Chidamide 20 mg BIW,PO; Day1-Day14, capecitabine 850-1000mg/m2, BID, PO) ；After completing the surgery, Post-operation 4 cycles of Capeox
CapeOX
4 cycles (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; Day1-Day14, capecitabine, 850-1000mg/m2, BID, PO. ） Post-operation 4 cycles of Capeox
RECRUITING
Daping Hospital， Third Military Medical University, Chongqing
Southwest Hospital, China
OTHER
Xinqiao Hospital of Chongqing
OTHER
First Affiliated Hospital of Chongqing Medical University
OTHER
The Second Affiliated Hospital of Chongqing Medical University
OTHER
Chongqing Medical University
OTHER
Chongqing University Cancer Hospital
OTHER
Chongqing General Hospital
OTHER
Chongqing Traditional Chinese Medicine Hospital
OTHER
Chongqing Shapingba District People's Hospital
UNKNOWN
Chongqing Seventh People's Hospital
UNKNOWN
Chongqing Renji Hospital, University of Chinese Academy of Sciences
OTHER_GOV
The 13th People's Hospital of Chongqing
UNKNOWN
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
OTHER